Psoriasis
Cosmeceutical Critique
Artemisia capillaris extract
Various parts of the shrub Artemisia capillaris, found abundantly in China, Japan, and Korea, have been used in traditional medicine in...
Latest News
Sustained response at 2 years reported for newly approved oral psoriasis agent
Long-term results with the JAK inhibitor for psoriasis show responses persist.
Original Research
Optimizing Narrowband UVB Phototherapy: Is It More Challenging for Your Older Patients?
Narrowband UVB (NB-UVB) phototherapy remains a safe and efficacious nonpharmacologic treatment for dermatologic conditions in older and younger...
Latest News
FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis
Approval was based on the results of two phase 3 trials of almost 1,700 adults with moderate to severe plaque psoriasis.
Practical Pearls
Surgical Deroofing for Hidradenitis Suppurativa
Hidradenitis suppurativa can present in varying degrees of severity; management often poses a challenge for primary care physicians and...
From the Journals
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?
Patients with isolated axial psoriatic arthritis (PsA) were older at diagnosis, more likely to have psoriatic nail lesions, and less likely to...
News from the FDA/CDC
FDA okays spesolimab, first treatment for generalized pustular psoriasis
The drug received priority review and had orphan drug and breakthrough therapy designation.
From the Journals
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Patients with immune-mediated inflammatory diseases have weaker vaccine-induced immunity to COVID but are able to build a humoral immune response...
Latest News
Asian patients with psoriasis have shortest visits, study shows
The reasons for the difference are unclear and in need of further research, according to the study authors.
News from the FDA/CDC
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.
From the Journals
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review reveals
While switches between biosimilars of the same reference biologic already occur for biosimilars with indications in different specialties, they do...